Project Grant R21HL188519
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $222K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $229,245 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period September 1, 2025 through August 31, 2027. This R03 award supports research to develop improved measurement methods for demographic variables and their associations with cardiovascular health disparities among U.S. adults. The research team...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $1,505,062 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a factorial trial optimizing dietary adherence in a mobile behavioral weight loss intervention for adults. The award funds a six-month randomized trial enrolling 580 adults in a smartphone-based weight loss program that combines daily calorie goals with mobile dietary self-monitoring...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Duke University $1,532,545 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze the effect of income-based health insurance benefit designs on cardiovascular disease outcomes and disparities among low-income workers. The research examines whether employers' selective provision of more generous health benefits—such as free cardioprotective medicines or low...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $459,838 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025 through July 31, 2027. This award supports software development and community engagement activities for the Cardinal open-source software infrastructure, which provides a unified computational platform for simulating all major aspects of...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $773,466 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 3, 2026, to investigate CXCL5-CXCR2 signaling mechanisms in macrophage cholesterol efflux and atherosclerosis prevention. The research integrates systems biology, pharmacology, and atherosclerosis expertise across three aims: elucidating CXCL5-CXCR2 signaling mechanisms using multi-omics and CRISPR-Cas9 in human...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,924 on July 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837) to support research on cell surface localization of Factor VIII mimetic therapy for hemophilia A treatment. The award funds a five-year project running through June 30, 2031, with work performed in Chapel Hill, North Carolina. The research addresses hemophilia A, an inherited bleeding disorder caused...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,248 on September 26, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research triangulating causal effects of sleep, inflammation, and cardiometabolic disease. The research will identify oxylipin biomarkers associated with sleep problems—including insomnia, sleep apnea, and short sleep duration—and their relationship to cardiometabolic disease. The study...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Heart, Lung, and Blood Institute awarded East Carolina University $561,100 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026 to develop a portable photoplethysmogram (PPG) prototype device and establish a platform method for noninvasive measurement of cardiometabolic disease biomarkers. The research develops a 2-site PPG data acquisition system to derive blood pressure waveform signals and extract biomarker panels including systolic and diastolic...